These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34151207)

  • 1. Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB
    Liu Z; Iyer MR; Godlewski G; Jourdan T; Liu J; Coffey NJ; Zawatsky CN; Puhl HL; Wess J; Meister J; Liow JS; Innis RB; Hassan SA; Lee YS; Kunos G; Cinar R
    ACS Pharmacol Transl Sci; 2021 Jun; 4(3):1175-1187. PubMed ID: 34151207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
    Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
    FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice.
    Song D; Bandsma RH; Xiao C; Xi L; Shao W; Jin T; Lewis GF
    Diabetologia; 2011 May; 54(5):1181-9. PubMed ID: 21340622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic targeting of the centrally active cannabinoid 1 receptor (CB
    Hirsch S; Hinden L; Naim MB; Baraghithy S; Permyakova A; Azar S; Nasser T; Portnoy E; Agbaria M; Nemirovski A; Golomb G; Tam J
    J Control Release; 2023 Jan; 353():254-269. PubMed ID: 36442615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice.
    Urs NM; Daigle TL; Caron MG
    Neuropsychopharmacology; 2011 Feb; 36(3):551-8. PubMed ID: 20980993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner.
    Nguyen PT; Schmid CL; Raehal KM; Selley DE; Bohn LM; Sim-Selley LJ
    Biol Psychiatry; 2012 Apr; 71(8):714-24. PubMed ID: 22264443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CB
    Drori A; Gammal A; Azar S; Hinden L; Hadar R; Wesley D; Nemirovski A; Szanda G; Salton M; Tirosh B; Tam J
    Elife; 2020 Nov; 9():. PubMed ID: 33210603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGIP1 alters internalization and modulates signaling of activated cannabinoid receptor 1 in a biased manner.
    Hájková A; Techlovská Š; Dvořáková M; Chambers JN; Kumpošt J; Hubálková P; Prezeau L; Blahos J
    Neuropharmacology; 2016 Aug; 107():201-214. PubMed ID: 26970018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.
    Cooper ME; Regnell SE
    Br J Clin Pharmacol; 2014 Jan; 77(1):21-30. PubMed ID: 23452341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the 'DRY' motif of the CB1 cannabinoid receptor result in biased receptor variants.
    Gyombolai P; Tóth AD; Tímár D; Turu G; Hunyady L
    J Mol Endocrinol; 2015 Feb; 54(1):75-89. PubMed ID: 25510402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid Receptor Interacting Protein 1a Competition with β-Arrestin for CB1 Receptor Binding Sites.
    Blume LC; Patten T; Eldeeb K; Leone-Kabler S; Ilyasov AA; Keegan BM; O'Neal JE; Bass CE; Hantgan RR; Lowther WT; Selley DE; Howlett AL
    Mol Pharmacol; 2017 Feb; 91(2):75-86. PubMed ID: 27895162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice.
    Chen W; Shui F; Liu C; Zhou X; Li W; Zheng Z; Fu W; Wang L
    Front Pharmacol; 2017; 8():707. PubMed ID: 29051736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle.
    Eckardt K; Sell H; Taube A; Koenen M; Platzbecker B; Cramer A; Horrighs A; Lehtonen M; Tennagels N; Eckel J
    Diabetologia; 2009 Apr; 52(4):664-74. PubMed ID: 19089403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of structurally novel G protein biased CB
    Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
    Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of cannabinoid 1 receptor in beta cells protects against high-fat/high-sugar diet-induced beta cell dysfunction and inflammation in murine islets.
    González-Mariscal I; Montoro RA; Doyle ME; Liu QR; Rouse M; O'Connell JF; Santa-Cruz Calvo S; Krzysik-Walker SM; Ghosh S; Carlson OD; Lehrmann E; Zhang Y; Becker KG; Chia CW; Ghosh P; Egan JM
    Diabetologia; 2018 Jun; 61(6):1470-1483. PubMed ID: 29497784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties.
    Urs NM; Gee SM; Pack TF; McCorvy JD; Evron T; Snyder JC; Yang X; Rodriguiz RM; Borrelli E; Wetsel WC; Jin J; Roth BL; O'Donnell P; Caron MG
    Proc Natl Acad Sci U S A; 2016 Dec; 113(50):E8178-E8186. PubMed ID: 27911814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.
    Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J
    Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
    Janero DR; Lindsley L; Vemuri VK; Makriyannis A
    Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic insulinopenia/hyperglycemia decreases cannabinoid CB
    Moura LIF; Lemos C; Ledent C; Carvalho E; Köfalvi A
    Brain Res Bull; 2019 Apr; 147():101-109. PubMed ID: 30721768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.